Prostate Cancer

Treating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures

Bone marrow failure may occur following treatment with radium-223 in a portion of patients with metastatic castration-resistant prostate cancer who have high skeletal tumor burden.

Dawn Hershman, MD, Associate Professor Medicine at Columbia University Medical Center, discusses the late-effects of intermittent androgen deprivation therapy (ADT) to continuous ADT in prostate cancer.

Nagi B. Kumar, PhD, Professor/Director, Cancer Chemoprevention, Moffitt Cancer Center, discusses the potential of green tea catechins for the prevention of prostate cancer.

Howard Sandler, MD, MS, FASTRO, chair, Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, discusses results from a phase III study on docetaxel with hormonal and radiation therapy in prostate cancer.

Treatment with an adjuvant combination of docetaxel, androgen deprivation therapy (ADT), and radiation therapy (RT) improved 4-year overall survival rates in patients with high-risk localized prostate cancer, when compared with ADT plus RT alone.

A. Karim Kader, MD, PhD, Minimally Invasive Surgery, Urology, Department of Surgery, University of California San Diego School of Medicine, discusses how prostate genetic score (PGS) stratifies baseline risk of prostate cancer and improves prostate-specific antigen (PSA) performance in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial.

Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses the impact of prostate-specific antigen (PSA) screening recommendations.